Pfizer, Inc.
PFE
Positions held
Your positionsPFE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Pfizer's strong market position in the healthcare sector allows it to leverage its extensive portfolio of drugs and vaccines, which can lead to sustained revenue growth.
- Pfizer's revenue increased by 4% compared to the prior quarter, reaching $15.0 billion.
- The company has a market capitalization of approximately $156.74 billion, indicating strong investor confidence.
- The pharmaceutical industry faces increasing regulatory scrutiny, which may impact Pfizer's ability to launch new products and maintain profitability.
- Pfizer's operating margin has compressed to 23.5%, down from 29.5% in the previous quarter.
- The company's net income was negative in the latest quarter, reporting a loss of $248 million.
Fundamentals
| Market cap | $158.56B | Enterprise value | $210.64B | Trailing P/E | 36.61 | Forward P/E | 9.60 |
| PEG | 12.81 | Price / book | 1.86 | Beta | 0.28 | Dividend yield | 6.18% |
| Revenue growth | 2.6% | Earnings growth | — | Gross margin | 74.7% | Operating margin | 27.9% |
| Profit margin | 6.8% | ROE | 5.0% | ROA | 5.8% | Debt / equity | 0.74 |
| Current ratio | 1.27 | Free cash flow | $12.49B | Analyst recommendation | buy | Mean target | $29.11 |
| 52w high | $29.21 | 52w low | $23.62 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $15.0B | $14.4B | $17.6B | $16.7B | $14.7B | — |
| Op margin | 23.5% | 29.5% | 21.0% | 33.2% | 25.7% | — |
| Net income | -$248M | $2.7B | -$1.6B | $3.5B | $2.9B | — |
| Gross margin | 72.8% | 75.4% | 70.0% | 74.9% | 74.2% | — |
| Gross profit | $10.9B | $10.9B | $12.3B | $12.5B | $10.9B | — |
| Operating income | $3.5B | $4.3B | $3.7B | $5.5B | $3.8B | — |
- Revenue +4% vs prior quarter ($15.0B vs $14.4B).
- Gross margin 72.8% (was 75.4% prior quarter).
- Operating margin compressed to 23.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $62.6B | $63.6B | $59.6B | $101.2B | — |
| Op margin | 27.8% | 23.5% | 7.4% | 37.7% | — |
| Net income | $7.8B | $8.0B | $2.1B | $31.4B | — |
| Gross margin | 74.3% | 71.9% | 58.1% | 66.1% | — |
| Gross profit | $46.5B | $45.8B | $34.6B | $66.8B | — |
| Operating income | $17.4B | $14.9B | $4.4B | $38.1B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
2026-10-09 · Moderna stock jumps on planned national cancer vaccine effort
2026-10-09 · Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
2026-10-09 · DBS Bank Adjusts Price Target on Pfizer to $35 From $30
2026-10-09 · Can Pfizer (PFE) Turn a Forward P/E Discount into Real Returns?
2026-10-09 · FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
2026-10-09 · Frontline TUKYSA Maintenance Approval Could Be A Game Changer For Pfizer (PFE)
2026-10-09 · BofA Securities Adjusts Pfizer Price Target to $29 From $27, Maintains Neutral Rating
2026-10-09 · Cancer Stocks to Consider as Oncology Innovation Accelerates
2026-10-09 · Roche Gets FDA Approval for Another Label Expansion of Tecentriq
2026-10-09 · Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks
2026-10-09 · Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Price (daily)
Full chart · RSI · MACD · patterns